Other News To Note

• Endocyte Inc., of West Lafayette, Ind., and Merck & Co. Inc., of Whitehouse Station, N.J., said the European Medicines Agency accepted for review a marketing authorization application for vintafolide (MK-8109/EC145) and the diagnostic imaging agent etarfolatide (EC20), which are in development for targeted treatment of folate-receptor-positive, platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin.